Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 5/20 | 0.61 |
| ▸ | NAMPT | P43490 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24648675 | 1.00 | QPCT (0.61) | QPCTNAMPTLMNASMN1; SMN2TP53 | |
| SCHEMBL29888531 | 0.81 | QPCT (0.52) | QPCTNAMPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL24648674 | 0.81 | QPCT (0.52) | QPCTNAMPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL29888527 | 0.79 | NAMPT (0.47) | QPCTNAMPTLMNASMN1; SMN2TP53 | |
| SCHEMBL29889141 | 0.78 | NAMPT (0.46) | QPCTNAMPTLMNASMN1; SMN2TP53 | |
| SCHEMBL77764 | 0.77 | QPCT (1.00) | QPCTSMN1; SMN2TP53MAPK1KMT2A | |
| SCHEMBL5217150 | 0.75 | QPCT (0.76) | QPCTNAMPTALOX15 | |
| SCHEMBL78603 | 0.75 | QPCT (1.00) | QPCTLMNASMN1; SMN2MAPK1KMT2A | |
| SCHEMBL27400268 | 0.74 | DYRK1A (0.49) | NAMPT | |
| SCHEMBL4781044 | 0.74 | L3MBTL1 (0.60) | QPCTNAMPTLMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | SAINT LOUIS UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| US-20220267312-A1 | AMINO BENZOTHIAZOLE COMPOUNDS FOR TREATMENT OF ANTIBIOTIC RESISTANT BACTERIA | SAINT LOUIS UNIVERSITY (US) | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267312-A1 | AMINO BENZOTHIAZOLE COMPOUNDS FOR TREATMENT OF ANTIBIOTIC RESISTANT BACTERIA | BCAT2, BCAT1, ABAT | QPCT 29/4885NAMPT 503/4885LMNA 3561/4885 |
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | BCAT1, BCAT2, IL4I1 | QPCT 160/4885NAMPT 4131/4885LMNA 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.